Cancer cachexia market seen reaching $3.35 billion by 2030

The Business Research Company says the cancer cachexia market grew to $2.6 billion in 2025 and is projected to reach $3.35 billion by 2030. The forecast reflects rising cancer cases, more attention to supportive oncology care and growing demand for therapies that target weight loss and muscle wasting.

Why it matters: - Cancer cachexia can weaken patients, reduce tolerance to cancer treatment and worsen survival outcomes. - Growth in the market signals more attention to supportive oncology care, including therapies aimed at preserving muscle and improving quality of life. - The market outlook also points to rising demand for personalized cachexia treatment as cancer cases increase worldwide.

What happened: - The Business Research Company projected the cancer cachexia market will grow to $3.35 billion by 2030. - The forecast implies a 5.1% compound annual growth rate from 2026 to 2030. - The market reached $2.6 billion in 2025 and is projected to rise to $2.75 billion in 2026. - The report was published Nov. 6, 2026, and is based in London. - The company made the report available as a free sample and a full report.

The details: - Cancer cachexia is a syndrome marked by progressive weight loss, muscle wasting, fatigue, weakness and loss of appetite in patients with cancer. - The condition is linked to systemic inflammation, metabolic disturbances and tumors. - The report cited several drivers behind market growth, including more late-stage cancer diagnoses, greater awareness among clinicians and wider distribution through hospital pharmacies. - Early uptake of anabolic treatments and broader supportive oncology care also supported recent growth. - Looking ahead, the report expects demand to be driven by personalized cachexia therapies, ongoing clinical research, outpatient oncology services and digital tools for patient monitoring. - The report also flagged combination drug therapies, muscle preservation strategies, nutritional supplementation, anti-inflammatory treatments and better monitoring of cachexia progression as major trends. - In 2025, North America held the largest market share. - The Asia-Pacific region is expected to be the fastest-growing market during the forecast period. - Other regions covered include South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report said cancer prevalence is a key driver, citing about 165,000 new cancer diagnoses in Australia in 2023, or more than 450 per day, with males making up about 55% of cases.

Between the lines: - The market is moving from general supportive care toward more targeted management of cachexia symptoms and disease progression. - The regional split suggests mature healthcare systems still dominate revenue, while faster growth is shifting toward markets with expanding access and rising cancer incidence. - The emphasis on digital monitoring and outpatient care suggests treatment is becoming less dependent on hospital-only settings.

What's next: - The market is expected to keep expanding through 2030 as cancer incidence rises and more therapies enter clinical development. - Companies and researchers are likely to focus on treatments that combine nutrition, inflammation control and muscle preservation. - The company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and market hotspot graphics. - The company also provided contact details for expert inquiries and promoted its LinkedIn, Facebook and X accounts.